Related Experiment Video
Updated: May 31, 2026

Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression
Published on: June 15, 2019
New approaches for empiric therapy in Gram-positive sepsis
M Bassetti1, F Ginocchio, D R Giacobbe
1Division of Infectious Diseases, San Martino Hospital and University of Genoa School of Medicine, Genoa, Italy. matteo.bassetti@hsanmartino.it
Abstract:
Nosocomial bloodstream infections (BSIs) have become an important cause of morbidity and mortality, particularly in intensive care units (ICUs). Gram-positive organisms are the prevalent causes of antibiotic-resistant BSI, especially Staphylococcus aureus, coagulase-negative staphylococci and enterococci. In recent years, several reports have shown an increase in antimicrobial resistance among Gram-positive bacteria isolated from patients in ICUs. In this context, methicillin-resistant Staphylococcus aureus (MRSA) is a major problem. In the ICU more than 50% of S. aureus isolates in Europe are resistant to methicillin. Although vancomycin became the drug of choice for MRSA and is still widely used for this indication, many studies suggest that when vancomycin MIC values are at the high end of the susceptibility range, vancomycin is less effective against MRSA. High MRSA prevalence combined with the widespread use of vancomycin for empirical Gram-positive coverage may lead to changes in patient outcomes. Here we describe the microbiological, pharmacological and clinical characteristics of three new antibacterials helpful in severe infections in ICU patients: linezolid, tigecycline and daptomycin. These new drugs have some limitations, and the possibility developing resistance is real. Knowledge of both old and new antibacterials is necessary to utilize them most effectively.
Insights
Nosocomial bloodstream infections (BSIs) are a significant threat in ICUs, often caused by antibiotic-resistant Gram-positive bacteria like MRSA. New antibacterials offer alternatives but require careful use due to potential resistance.
Area of Science:
- Infectious Diseases
- Critical Care Medicine
- Pharmacology
Background:
- Nosocomial bloodstream infections (BSIs) are a major cause of illness and death in intensive care units (ICUs).
- Gram-positive bacteria, particularly methicillin-resistant Staphylococcus aureus (MRSA), are increasingly resistant to antibiotics, posing a significant challenge in ICUs.
- Vancomycin, the standard treatment for MRSA, shows reduced effectiveness when its minimum inhibitory concentration (MIC) is high.
Purpose of the Study:
- To review the microbiological, pharmacological, and clinical profiles of three novel antibacterials: linezolid, tigecycline, and daptomycin.
- To highlight their utility in treating severe infections in ICU patients.
- To emphasize the importance of understanding both existing and new antibiotics for effective management.
Main Methods:
- Review of microbiological, pharmacological, and clinical data for linezolid, tigecycline, and daptomycin.
- Analysis of current trends in antibiotic resistance among Gram-positive bacteria in ICUs.
- Evaluation of vancomycin efficacy in relation to MIC values.
Main Results:
- Linezolid, tigecycline, and daptomycin are identified as valuable agents for severe infections in ICUs.
- The emergence of resistance to these new agents is a potential concern.
- High prevalence of MRSA and the widespread use of vancomycin necessitate alternative treatment strategies.
Conclusions:
- Effective management of BSIs in ICUs requires a comprehensive understanding of both traditional and novel antibacterial agents.
- Careful consideration of antibiotic resistance patterns and drug efficacy is crucial for optimizing patient outcomes.
- Linezolid, tigecycline, and daptomycin represent important additions to the therapeutic arsenal against resistant Gram-positive infections, but their use must be judicious to preserve efficacy.
More Related Videos
12:03Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
Published on: April 18, 2019
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
Related Concept Videos
Acute Pyelonephritis II: Diagnostic Studies and Management
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Inhibitors of Gram-positive Cell Wall Synthesis
Clinical Significance of Antibiotic Resistance
Urine Studies II: Urine Culture and Sensitivity Test
Mechanism of Antibiotic Resistance in MRSA